Arterial Line Patency in ICU Bound COVID-19 Patients

NCT04992221 | Completed DMC

• 1 other identifier: MRC-01-21-492
• Study Type: observational
• Target: 245
• Locations: 1 country
• Sites: 1

Brief Summary

The health care system was completely overwhelmed by the SARS-Cov-2 virus, and ICU admissions soared as a result of the ICU doctors' increased workload. A committed crew inserts invasive line procedures to guarantee a secure and efficient performance. When COVID-19 bound patients were followed up on in the second wave, frequent requests for arterial line placement were noted. These critically ill individuals had high rates of thrombosis, which was linked to thrombotic consequences. Many factors, such as patient morbidities, insertion technique, and operational health care trained personnel's qualifications, contribute to the lowering of arterial line patency. Our ICU management committee approved the use of systemic anticoagulation of ICU admitted patients starting on March 21, 2021 in response to an increase in the incidence of thrombosis and pulmonary embolic events in patients with COVID-19 admitted to the ICU in the second wave of the epidemic.

Conditions

SARS-CoV-2 ICU Bound

Keywords

SARS-CoV-2; arterial line patency; Risk factors; ICU

Outcome Measures

Primary Outcomes (1)

• Incidence of arterial line failure in ICU bound COVID-19 patients

  60-90 days

Secondary Outcomes (1)

• Risk factors affecting the arterial line patency

  6 months

Interventions

arterial line PROCEDURE

arterial line inserted for invasice mointroing and sampling

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Consecutive ICU patients at HMGH Hospital; Hamad Medical Corporation with continuous invasive monitoring will be enrolled if they met following eligibility criteria: peripheral artery cannulation with a suitable arterial cannula and a functional arterial line established after insertion.

You may qualify if:

• Consecutive ICU patients at HMGH Hospital; Hamad Medical Corporation with continuous invasive monitoring will be enrolled if they met following eligibility criteria: peripheral artery cannulation with a suitable arterial cannula and a functional arterial line established after insertion.

You may not qualify if:

• Other pateints with COVID-19 NOT ICU bound

Sponsors & Collaborators

• Hamad Medical Corporation: lead

Study Sites (1)

HAMAD Medical Corporation

Doha, 82228, Qatar

Location

MeSH Terms

Interventions

Vascular Access Devices

Intervention Hierarchy (Ancestors)

Catheters; Equipment and Supplies

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 4, 2021
• First Posted: August 5, 2021
• Study Start: February 1, 2021
• Primary Completion: March 31, 2022
• Study Completion: April 1, 2022
• Last Updated: November 14, 2022

Record last verified: 2021-02

Data Sharing

• IPD Sharing: Will not share

Locations

QA (1)